Therapeutic Indications of Skyrizi Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. And treatment of active psoriatic arthritis in adults. Treatment of moderately to severely active Crohn's disease in adults. Method Of Administration of Skyrizi • Visually inspect SKYRIZI for particulate matter and discoloration prior to administration. The solution may contain a few translucent to white particles. ◦ SKYRIZI 150 mg/mL and 360 mg/2.4 mL: a colorless to yellow, and clear to slightly opalescent solution. ◦ SKYRIZI 75 mg/0.83 mL and 600 mg/10 mL: a colorless to slightly yellow, and clear to slightly opalescent solution. ◦ Do not use if the solution contains large particles or is cloudy or discolored. • Discard after use. Do not reuse. Recommended Dosage for Plaque Psoriasis The recommended dosage is 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. Recommended Dosage for Psoriatic Arthritis The recommended dosage is 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. Recommended Dosage for Crohn’s Disease Adult Patients: Induction The recommended induction dosage of SKYRIZI is 600 mg administered by intravenous infusion over a period of at least one hour at Week 0, Week 4, and Week 8. Adult Patients: Maintenance The recommended maintenance dosage of SKYRIZI is 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Warnings and Special Precautions While Taking SKYRIZI Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately.